SCHEMBL6296165

SCHEMBL6296165

Nc1ccc(Cl)c2ncccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 4/20 0.72
HSP90AA1 P07900 7/20 0.61
HSP90AB1 P08238 3/20 0.61
IDO1 P14902 1/20 0.61
PSMB5 P28074 1/20 0.61
MMP14 P50281 3/20 0.54
MAPT P10636 5/20 0.52
LMNA P02545 4/20 0.52
KDM4E B2RXH2 3/20 0.52
METAP2 P50579 2/20 0.52
METAP1 P53582 2/20 0.52
BRD4 O60885 1/20 0.52
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
APAF1 O14727 1/20 0.50
TDP2 O95551 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31434767 0.84 HSP90AA1 (0.61) NR4A2HSP90AA1HSP90AB1IDO1PSMB5
SCHEMBL2423195 0.84 HSP90AA1 (0.61) NR4A2HSP90AA1HSP90AB1IDO1PSMB5
SCHEMBL10009591 0.84 NR4A2 (1.00) NR4A2HSP90AA1HSP90AB1IDO1PSMB5
SCHEMBL196536 0.83 KDM4E (0.70) NR4A2HSP90AA1MMP14MAPTLMNA
SCHEMBL7455899 0.83 HSP90AA1 (0.70) NR4A2HSP90AA1HSP90AB1IDO1PSMB5
SCHEMBL29661959 0.83 HSP90AA1 (0.70) NR4A2HSP90AA1HSP90AB1IDO1PSMB5
SCHEMBL18980424 0.76 KMT2A (0.59) NR4A2HSP90AA1MMP14MAPTLMNA
SCHEMBL29777332 0.76 KMT2A (0.59) NR4A2HSP90AA1MMP14MAPTLMNA
SCHEMBL3559305 0.76 KDM4E (0.61) NR4A2HSP90AA1IDO1MMP14MAPT
SCHEMBL9185003 0.76 KDM4E (0.72) NR4A2HSP90AA1HSP90AB1IDO1PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 US disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 EP disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 WO disclosed
US-6875764-B1 Urea and thiourea compounds useful for treatment of coccidiosis NEW PHARMA RESEARCH SWEDEN AB (SE) 2005-04-05 US disclosed
EP-1224165-A1 NOVEL COMPOUNDS New Pharma Research Sweden AB (SE) 2002-07-24 EP disclosed
WO-2001030749-A1 NOVEL COMPOUNDS NEW PHARMA RESEARCH SWEDEN AB (SE) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 NR4A2 2643/4885HSP90AA1 3636/4885HSP90AB1 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.